Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Features of Pancreas and Biliary Tract Cancers Related to Lynch Syndrome

Lynch 증후군과 관련된 췌장담도암의 임상적 특성

  • Yoon Suk Lee (Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine)
  • 이윤석 (인제대학교 의과대학 일산백병원 내과학교실)
  • Received : 2023.11.06
  • Accepted : 2023.12.04
  • Published : 2023.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009;41:112-117. https://doi.org/10.1038/ng.283
  2. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932. https://doi.org/10.1056/NEJMra012242
  3. Zalevskaja K, Mecklin JP, Seppala TT. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: a retrospective analysis from the Finnish National Lynch Syndrome Research Registry. Front Oncol 2023;13:1123901. https://doi.org/10.3389/fonc.2023.1123901
  4. Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017;66:464-472. https://doi.org/10.1136/gutjnl-2015-309675
  5. Moller P, Seppala T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut 2017;66:1657-1664. https://doi.org/10.1136/gutjnl-2016-311403
  6. Therkildsen C, Jensen LH, Rasmussen M, Bernstein I. An update on immune checkpoint therapy for the treatment of Lynch syndrome. Clin Exp Gastroenterol 2021;14:181-197. https://doi.org/10.2147/CEG.S278054
  7. Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23:659-670. https://doi.org/10.1016/S1470-2045(22)00197-8
  8. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2021;1. https://doi.org/10.1056/EVIDoa2200015
  9. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-1865. https://doi.org/10.1016/S0140-6736(23)00727-4 Erratum in: Lancet 2023;402:964. https://doi.org/10.1016/S0140-6736(23)01904-9